rachnatshroff Profile Banner
Rachna Shroff, MD, MS, FASCO Profile
Rachna Shroff, MD, MS, FASCO

@rachnatshroff

Followers
5K
Following
14K
Media
618
Statuses
4K

GI Oncologist, focus pancreatic, biliary cancers, personalized tx’s. Love to dance, travel, and spend time with my family. ASCO FCOI: https://t.co/oXHqwATEeE

University of Arizona
Joined October 2012
Don't wanna be here? Send us removal request.
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
4 days
RT @AnaVManana: 🚨 Leadership isn’t built alone! .Join us in Arizona for #LEAD2025 — a unique space to recharge, connect, and grow as leader….
0
15
0
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
20 days
RT @doctorpemm: 👉👉👉Lovely to have the cherished opportunity to give a toast 🥂 along with @rachnatshroff to an all-time amazing couple .@ni….
0
4
0
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
29 days
There are some moments that need no caption…@ninashah33 and @DoctorGRao brought the #getRAOdy all weekend!
Tweet media one
Tweet media two
Tweet media three
6
1
42
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
30 days
RT @Latinamd: Look at you tonight! . Lovely to celebrate the beautiful bride (myeloma queen) @ninashah33 and participate in my first ever….
0
1
0
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
1 month
RT @OncLive: Shubham Pant, MD, MBBS and @rachnatshroff highlight how recent breakthroughs in KRAS-specific inhibitors—such as those targeti….
0
7
0
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
Now THIS is out of office…
Tweet media one
Tweet media two
Tweet media three
2
0
32
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
0
7
0
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
RT @Larvol: The Top Most Active Cancer Institutes that were leading the conversation during @myESMO Gastrointestinal (GI) Cancers Annual Co….
0
13
0
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
RT @Larvol: Top Women Oncologists from @myESMO Gastrointestinal (GI) Cancers Annual Congress 2025. Explore more #ESMOGI25 insights and data….
0
9
0
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
RT @Larvol: Top Oncologists from @myESMO Gastrointestinal (GI) Cancers Annual Congress 2025. Explore more #ESMOGI25 insights and data: http….
0
10
0
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
RT @NazliDizman: 🙋‍♀️Hello!! How's your schedule this fall? .🌟#WomenInOncology, save Sep 27-28 for #LEAD25!.It's a fantastic opportunity fo….
0
17
0
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
RT @DrShubhamPant: And that’s a wrap on #ESMOGI in vibrant Barcelona! Honored to chair the #KRAS in pancreatic cancer symposium, present th….
0
2
0
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
#ESMOGI25 orals: as always, @LorenzaRimassa puts it all in perspective 😎 #ESMOAmbassadors @myESMO
Tweet media one
Tweet media two
2
5
13
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
#ESMOGI25 orals: CM 9DW QOL in #HCC .@myESMO #ESMOAmbassadors.- Nivo/Ipi with ⬇️ HrQOL deterioration .- PROs show less bother from side effects with Nivo/Ipi.- No negative impact of TRAE related 🛑 on efficacy
Tweet media one
Tweet media two
0
5
16
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
#ESMOGI25 orals: TALENTACE, TACE plus Atezo/Bev in intermediate to high tumor burden #HCC.- ⬆️ TACE-PFS 11.3 vs 7 mths.- ORR 49 vs 34%.- OS immature .#ESMOAmbassadors @myESMO
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
3
11
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
#ESMOGI25 orals: CM 8HW QOL.- Nivo/Ipi in MSI-H/dMMR #CRC.- No ⬇️ in HrQOL .- Given known potential tox, reassuring data.@myESMO #ESMOAmbassadors
Tweet media one
Tweet media two
Tweet media three
0
1
10
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
#ESMOGI25 orals: PANOVA-3 QOL is out ‼️ @MacarullaTeresa .- ⬆️ global QOL.- ⬇️ time to deterioration for pain.- ⬇️ opioid use .TTF needing to be worn 18 hrs/day ⁉️ @myESMO #ESMOAmbassadors
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
1
9
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
#ESMOGI25 orals: MATTERHORN PROs are here 👏:.- PRO compliance rate high ✅.- No decline in QOL with FLOT + D .- Anxiety 📉 after therapy .#ESMOAmbassadors @myESMO @salahAlBatran
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
11
19
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
Beyond PDL1 for #HCC - great overview by Dr. Stephen Chan. 🔑 takeaways:.- Multiple novel 🎯 .- cell therapies coming 🥳.- T cell engagers 🧐 .#ESMOGI25 #ESMOAmbassadors @myESMO
Tweet media one
Tweet media two
Tweet media three
1
0
9
@rachnatshroff
Rachna Shroff, MD, MS, FASCO
2 months
Excellent summary for intermediate stage #HCC by @GIcancerDoc! Progress but many ❓🤨:.- Is PFS the right endpoint?.- TACE vs TARE.- Sequence vs concurrent.#ESMOGI25 #ESMOAmbassadors @myESMO
Tweet media one
Tweet media two
Tweet media three
Tweet media four
1
10
31